CU23432B6 - Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras - Google Patents

Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Info

Publication number
CU23432B6
CU23432B6 CU20050213A CU20050213A CU23432B6 CU 23432 B6 CU23432 B6 CU 23432B6 CU 20050213 A CU20050213 A CU 20050213A CU 20050213 A CU20050213 A CU 20050213A CU 23432 B6 CU23432 B6 CU 23432B6
Authority
CU
Cuba
Prior art keywords
proportions
potential
formulations containing
containing gamma
stabilized formulations
Prior art date
Application number
CU20050213A
Other languages
English (en)
Inventor
Angulo Lorenzo Anasagasti
Meireles Rolando Paez
Vega Yanelda Garcia
Milian Hector Santana
Barreto Ana Aguilera
Rivero Iraldo Bello
Saura Pedro Antonio Lopez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20050213A priority Critical patent/CU23432B6/es
Priority to CN201510078548.2A priority patent/CN104826094A/zh
Priority to RU2008121874/15A priority patent/RU2403057C2/ru
Priority to KR1020087013121A priority patent/KR101363237B1/ko
Priority to PT68052547T priority patent/PT1958643T/pt
Priority to ES06805254.7T priority patent/ES2619632T3/es
Priority to AU2006310918A priority patent/AU2006310918B2/en
Priority to JP2008538252A priority patent/JP5366551B2/ja
Priority to US12/092,440 priority patent/US8535657B2/en
Priority to CNA2006800502425A priority patent/CN101351219A/zh
Priority to ARP060104701A priority patent/AR056586A1/es
Priority to BRPI0618197-0A priority patent/BRPI0618197B1/pt
Priority to EP06805254.7A priority patent/EP1958643B1/en
Priority to PCT/CU2006/000011 priority patent/WO2007051431A2/es
Priority to CA2629895A priority patent/CA2629895C/en
Priority to ZA200804256A priority patent/ZA200804256B/xx
Publication of CU23432B6 publication Critical patent/CU23432B6/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

La presente invención está relacionada con formulaciones farmacéuticas estables para ser aplicadas por vía parenteral [líquidas o liofilizadas], o tópica [gel, ungüento o crema] que comprenden diferentes cantidades de los interferones recombinantes gamma y alfa en proporciones potenciadoras para el tratamiento de eventos patológicos que contemplan el crecimiento celular no fisiológico benigno o maligno de tejidos u órganos.
CU20050213A 2005-11-02 2005-11-02 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras CU23432B6 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CU20050213A CU23432B6 (es) 2005-11-02 2005-11-02 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
CN201510078548.2A CN104826094A (zh) 2005-11-02 2006-10-27 包含增效比例的干扰素γ和α的稳定的制剂
RU2008121874/15A RU2403057C2 (ru) 2005-11-02 2006-10-27 Стабильные фармацевтические составы, которые содержат интерфероны гамма и альфа в синергичных соотношениях
KR1020087013121A KR101363237B1 (ko) 2005-11-02 2006-10-27 증강된 비율의 감마 인터페론 및 알파 인터페론을 포함하는안정화된 제형
PT68052547T PT1958643T (pt) 2005-11-02 2006-10-27 Formulações estáveis que contêm proporções de aprimoramento de interferões-gama e -alfa
ES06805254.7T ES2619632T3 (es) 2005-11-02 2006-10-27 Formulaciones estables que contienen interferones gamma y alfa en proporciones potenciadoras
AU2006310918A AU2006310918B2 (en) 2005-11-02 2006-10-27 Stable formulations containing enhancing proportions of gamma- and alpha-interferons
JP2008538252A JP5366551B2 (ja) 2005-11-02 2006-10-27 相乗的効果を奏する割合でγ−及びα−インターフェロンを含有する安定化製剤
US12/092,440 US8535657B2 (en) 2005-11-02 2006-10-27 Stabilized pharmaceutical formulations that contain the interferons gammas and alpha in synergistic proportions
CNA2006800502425A CN101351219A (zh) 2005-11-02 2006-10-27 包含增效比例的干扰素γ和α的稳定的制剂
ARP060104701A AR056586A1 (es) 2005-11-02 2006-10-27 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
BRPI0618197-0A BRPI0618197B1 (pt) 2005-11-02 2006-10-27 Formulações farmacêuticas estáveis
EP06805254.7A EP1958643B1 (en) 2005-11-02 2006-10-27 Stable formulations containing enhancing proportions of gamma- and alpha-interferons
PCT/CU2006/000011 WO2007051431A2 (es) 2005-11-02 2006-10-27 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
CA2629895A CA2629895C (en) 2005-11-02 2006-10-27 Stable formulations containing enhancing proportions of gamma- and alpha-interferons
ZA200804256A ZA200804256B (en) 2005-11-02 2008-05-16 Stable formulations containing enhancing proportions of gamma- and alpha-interferons

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050213A CU23432B6 (es) 2005-11-02 2005-11-02 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Publications (1)

Publication Number Publication Date
CU23432B6 true CU23432B6 (es) 2009-10-16

Family

ID=40269648

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20050213A CU23432B6 (es) 2005-11-02 2005-11-02 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Country Status (15)

Country Link
US (1) US8535657B2 (es)
EP (1) EP1958643B1 (es)
JP (1) JP5366551B2 (es)
KR (1) KR101363237B1 (es)
CN (2) CN104826094A (es)
AR (1) AR056586A1 (es)
AU (1) AU2006310918B2 (es)
BR (1) BRPI0618197B1 (es)
CA (1) CA2629895C (es)
CU (1) CU23432B6 (es)
ES (1) ES2619632T3 (es)
PT (1) PT1958643T (es)
RU (1) RU2403057C2 (es)
WO (1) WO2007051431A2 (es)
ZA (1) ZA200804256B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
EP2266588A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for cancer therapy based on co-administration of a parovirus and a cytokine
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
PT2377516E (pt) * 2010-04-14 2012-07-02 Braun Melsungen Ag Composição acetaminofeno
RU2482871C2 (ru) * 2010-06-07 2013-05-27 Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") Композиция для лечения вирусных заболеваний животных
JP2013532661A (ja) 2010-07-22 2013-08-19 リベン ファーマシューティカルズ インコーポレイテッド 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
EA201301205A1 (ru) * 2011-04-27 2014-04-30 Носшор Юнивесити Хелссистем Способ предупреждения и/или лечения плоскоклеточного рака головы и шеи и композиция в нем используемая
RU2524651C1 (ru) * 2013-06-20 2014-07-27 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме раствора для инъекций и способ ее получения
CN104043110B (zh) * 2014-03-28 2016-05-04 上海交通大学 干扰素温敏水凝胶及其制备方法和应用
WO2019059804A1 (ru) 2017-09-25 2019-03-28 Георгий Георгиевич ЧУМБУРИДЗЕ Термостабильная композиция, обладающая антивирусной и антибактериальной активностью и ее использование
KR102546138B1 (ko) * 2017-12-07 2023-06-23 리벤 아이피 홀드코 엘엘씨 대사 상태의 치료를 위한 조성물 및 방법
CN114222566A (zh) * 2019-06-12 2022-03-22 雷文知识产权控股有限公司 用于改善癌症患者的结果的方法和组合物
CU20200029A7 (es) * 2020-05-20 2022-01-13 Ct Ingenieria Genetica Biotecnologia Composición farmacéutica para el tratamiento de enfermedades respiratorias de origen viral
CN114015758B (zh) * 2021-10-15 2022-06-24 无锡百泰克生物技术有限公司 一种冻干保护剂、荧光pcr检测试剂盒及冻干工艺
AU2022378720A1 (en) * 2021-10-26 2024-02-29 Georgia State University Research Foundation, Inc. SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER
CN115068592A (zh) * 2022-06-27 2022-09-20 长春生物制品研究所有限责任公司 开封后常温稳定的重组人干扰素α1b滴眼液及制备方法
CN115105584B (zh) * 2022-06-28 2023-03-31 长春生物制品研究所有限责任公司 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
EP0080879B1 (en) 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
DE3262575D1 (en) 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
ZA828580B (en) * 1981-12-23 1983-10-26 Schering Corp Interferon formulations
EP0107498B1 (en) 1982-10-25 1990-05-16 Genentech, Inc. Synergistic human interferon activity
US4499072A (en) 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
DK131986A (da) * 1985-03-25 1986-09-26 Schering Corp Stabilt gammainterferonpraeparat
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
US5028422A (en) 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5002764A (en) 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
US5024833A (en) 1988-03-10 1991-06-18 Industrial Farmaceutica Serono Spa Combined interferon/antiestrogen therapy for treatment of breast cancer
EP0276120B1 (en) * 1987-01-20 1992-04-08 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
US5190751A (en) 1987-01-20 1993-03-02 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
US4895716A (en) 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
US5256410A (en) 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US5444064A (en) 1989-02-28 1995-08-22 Montefiore Medical Center Method of treating gastrointestinal malignancies
CA2024046A1 (en) * 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
US5236707A (en) 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
AU674306B2 (en) 1992-02-10 1996-12-19 Interferon Sciences Inc. Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
GB9226729D0 (en) 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
CA2155005C (en) * 1993-02-02 1999-04-06 Weldon Courtney Mcgregor Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
US5814640A (en) 1994-10-04 1998-09-29 Montefiore Medical Center Method of treating gastrointestinal malignancies
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US7067546B2 (en) * 2001-08-03 2006-06-27 Takeda Pharmaceutical Company Crystal and process for producing the same
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
JP5057648B2 (ja) * 2002-09-26 2012-10-24 塩野義製薬株式会社 安定化されたタンパク組成物
KR20050085593A (ko) * 2002-12-13 2005-08-29 오츠카 세이야쿠 가부시키가이샤 경폐 투여용 동결-건조 인터페론-γ 조성물 및 그의 흡입시스템
AU2003299962A1 (en) * 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
JP2005162663A (ja) * 2003-12-02 2005-06-23 Asahi Denka Kogyo Kk 皮膚用基剤
US20050123576A1 (en) * 2003-12-03 2005-06-09 Ilana Lavon Mupirocin compositions for topical use, an improved process of making same and methods of using same
EP2102748B1 (en) * 2006-12-22 2012-02-01 International Business Machines Corporation System and method for recovery of memory transactions

Also Published As

Publication number Publication date
CA2629895A1 (en) 2007-05-10
ZA200804256B (en) 2009-05-27
JP5366551B2 (ja) 2013-12-11
EP1958643B1 (en) 2016-12-28
BRPI0618197B1 (pt) 2021-06-29
WO2007051431A2 (es) 2007-05-10
CN104826094A (zh) 2015-08-12
AU2006310918A1 (en) 2007-05-10
ES2619632T3 (es) 2017-06-26
JP2009513682A (ja) 2009-04-02
AR056586A1 (es) 2007-10-10
RU2403057C2 (ru) 2010-11-10
KR20080065684A (ko) 2008-07-14
PT1958643T (pt) 2017-03-23
US20090304628A1 (en) 2009-12-10
WO2007051431A3 (es) 2007-06-28
AU2006310918B2 (en) 2012-09-27
EP1958643A2 (en) 2008-08-20
US8535657B2 (en) 2013-09-17
CN101351219A (zh) 2009-01-21
BRPI0618197A2 (pt) 2013-01-08
KR101363237B1 (ko) 2014-02-12
RU2008121874A (ru) 2009-12-10
CA2629895C (en) 2016-08-30

Similar Documents

Publication Publication Date Title
CU23432B6 (es) Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
BR9814698A (pt) Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
DE602004026647D1 (de) Topische zusammensetzungen mit phosphorylierten polyphenolen
BRPI0615265A8 (pt) composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
ATE291416T1 (de) Topische zusammensetzungen zur erhöhung der glutathion produktion
ATE499098T1 (de) Verwendung von parp-1-hemmern
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BR9906908A (pt) Partìculas de glìter, artigo compósito, dispersão, combinação dispersìvel, composto de moldagem, e, composições moldável por injeção, cosmética tópica medicamentosa e compreendendo o glìter.
NZ594746A (en) Inhibitors of iap
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
DE502005010427D1 (de) Physiologisch aktive zusammensetzung gegen diabetes
BRPI0606520A2 (pt) tripeptìdeo e tetrapeptìdeo tioéteres
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
GT200900126A (es) Novedosos anticuerpos antiproliferacion
EP1853280A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CARDIOMYOPATHY AND CARDIAC DISEASES
AU5314900A (en) Compositions and methods for inhibiting cell death
BRPI0416690A (pt) derivados de pirrol
GB2451196A (en) Compositions and methods for promoting the healing of tissue of multicellular organisms
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej
DE602004018647D1 (de) Galloylpeptide
WO2003018598A3 (en) Monosaccharide derivatives
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite